CLINICAL_TRIALS
trial_result
· 2024-10-08
Clinical Trial Update: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease [Phase 3]
Summary
A Phase 3 study evaluating REPLAGAL (agalsidase alfa) in treatment-naive Chinese participants with Fabry disease has completed and posted results as of 2024-10-…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-10-08